Clinical Research Directory
Browse clinical research sites, groups, and studies.
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of T-cell acute lymphoblastic leukemia (T-ALL): multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T cells (CTLs) and immune modified dendritic cell vaccine (DCvac). This approach is aimed to achieve NGS MRD negativity in T-ALL patients, which can identify a very low risk of relapse and define patients with possible long-term remission without further treatment.
Official title: NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-cell Acute Lymphoblastic Leukemia
Key Details
Gender
All
Age Range
6 Months - 65 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-06-01
Completion Date
2030-12-31
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
Antigen-specific T cells CAR-T/CTL and DCvac
Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
Locations (1)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China